Cancer Network: Chemo Plus Veliparib Improves Responses in BRCA-Mutant Breast Cancer

Adding the PARP inhibitor veliparib to carboplatin and paclitaxel chemotherapy significantly increased response rates among women with BRCA1 or BRCA2 mutations and locally recurrent or metastatic breast cancer, according to a randomized phase II trial.

Read the full story at Cancer Network

Share This Article!